Elixiron Immunotherapeutics develops therapeutics for cancer and immunological diseases using phage display and single human B cell cloning to create biologics and small molecule inhibitors. Their focus includes targeting specific pathways such as IFN-γ and CSF1R to address conditions like vitiligo, Alzheimer's disease, and various cancers.
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and immunological diseases lack effective treatments due to complex underlying mechanisms and the absence of targeted therapies. Conditions like vitiligo, Alzheimer's disease, and certain cancers present significant challenges in drug development because of the intricate interplay of immune pathways and the need for precise therapeutic interventions.
Solution
Elixiron Immunotherapeutics develops innovative therapies for cancer and immunological diseases by leveraging translational medicine to identify clinical targets and create targeted drug modalities. The company utilizes phage display and single human B cell cloning platforms to generate biologics and small molecule inhibitors. Elixiron focuses on specific pathways, such as IFN-γ and CSF1R, to address the root causes of these diseases. Their pipeline includes drug candidates in various stages of development, from research to Phase 2/3 clinical trials, aimed at bringing next-generation immunotherapies to patients.
Target Audience
The primary target audience includes patients suffering from cancer, vitiligo, Alzheimer's disease, and other immunological disorders, as well as healthcare providers and clinical researchers seeking advanced therapeutic options.
Features
- Development of biologics using phage display and single human B cell cloning platforms
- Small molecule inhibitor development targeting specific pathways
- Indemakitug (EI-001): An antibody targeting IFN-γ for vitiligo and hemophagocytic lymphohistiocytosis (HLH), currently in Phase 1 clinical trials
- Enrupatinib (EI-1071): A CSF1R small molecule inhibitor for Alzheimer's disease and tenosynovial giant cell tumors, also in Phase 1
- Pipeline of undisclosed antibody and bifunctional candidates in research stages for various cancer indications
- Focus on immunometabolism to identify novel drug targets